HCV Product Pipeline

 DiscoveryPreclinicalPhase 1Phase 2Phase 3
 Discovery Preclinical Phase 1 Phase 2 Phase 3
Compounds      
ACH-3102NS5A Inhibitor    
  
    
ACH-2684NS3/4A Protease Inhibitor   
  
    
SovaprevirNS3/4A Protease Inhibitor    
  
    
ACH-3422Nucleotide NS5B Polymerase Inhibitor  
  
    

About Achillion

Headquartered in New Haven, CT, Achillion is a leading-edge pharmaceutical company advancing multiple candidates with proven mechanisms for the treatment of HCV. Click here for more information about Achillion's ongoing clinical trials.

HCV Education

About the Hepatitis C Virus

Hepatitis C is a worldwide epidemic affecting more than 170 million individuals. Click to learn more about this disease.

No upcoming events at this time.

built@zoomedia
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue